Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

Under the terms of the Transaction, TILT will transition ownership of its Taunton dispensary to In Good Health, a private single-state cannabis operator, and shut down its Brockton dispensary for $2 ...

Immersive exhibition reimagines art through multi-sensory experience to improve the accessibility of visual arts for those with visual impairments.Blending technology, innovation, and creativity, ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...

Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat.com reports. Four ...

The company is also advancing cytokine antagonists imsidolimab, targeting IL-36R for generalized pustular psoriasis, and etokimab, an IL-33 antagonist. Anaptys is headquartered in San Diego, ...

In the 45-patient GEMINI-1 Phase 3 trial, patients were randomized 1:1:1 to receive a single infusion of 750mg intravenous (IV) imsidolimab, 300mg IV imsidolimab or placebo at Day 0. Of the ...

AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others .The Acne Vulgaris epidemiology based on gender analyzed that females are predominantly affected compared to males .The Acne Vulgaris ...